Neurologic complications in intensive care

Current Opinion in Critical Care

Volumn 7, Issue 2, 2001, Pages 68-73

  Barlas, Imran ^a   Oropello, John M ^a,b   Benjamin, Ernest ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DISEASE; CRITICAL ILLNESS; DISABILITY; HOSPITALIZATION; HUMAN; INTENSIVE CARE; LENGTH OF STAY; NEUROLOGICAL COMPLICATION; REVIEW; RISK FACTOR; SEPSIS;

BRAIN DISEASES, METABOLIC; COMORBIDITY; CRITICAL ILLNESS; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; NERVOUS SYSTEM DISEASES; RISK ASSESSMENT; SEPSIS; SURVIVAL ANALYSIS;

EID: 0035010966     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200104000-00003     Document Type: Review

References (63)

1. Neurologic complications in the intensive care unit
2. Neurologic complications of critical medical illnesses
3. Infection: Impaired consciousness as the initial symptom: Clinical and pathophysiologic aspects of septic encephalopathy
4. The spectrum of septic encephalopathy: Definitions, etiologies, and mortalities
5. The encephalopathy of sepsis
6. Septic encephalopathy
7. L-arginine pathway in the sepsis syndrome
8. The role of hypotension in septic encephalopathy following surgical procedures
9. Hypothermia
10. Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis
11. Partial pressure of ammonia versus ammonia in hepatic encephalopathy
12. Breath and blood ammonia in liver cirrhosis
13. Subclinical hepatic encephalopathy: Role of tryptophan binding to albumin and the competition with indole-3-acetic acid
14. Tryptophan metabolism and hepatic encephalopathy: Studies on the sedative properties of oxindole
15. Complications of cirrhosis: III. Hepatic encephalopathy
16. Relationship between cerebral perfusion in frontal-limbic-basal ganglia circuits and neuropsychologic impairment in patients with subclinical hepatic encephalopathy
17. Outcome of cardiopulmonary resuscitation in the intensive care setting
18. Outcome after cardiopulmonary resuscitation in a medical intensive care unit
19. Neuron-specific enolase and myelin basic protein: Relationship of cerebrospinal fluid concentrations to the neurologic condition of asphyxiated full-term infants
20. Neurological outcome after out-of-hospital cardiac arrest: Prediction by cerebrospinal fluid enzyme analysis
21. CSF and serum brain-specific creatine kinase isoenzyme (CK-BB), neuron-specific enolase (NSE) and neural cell adhesion molecule (NCAM) as prognostic markers for hypoxic brain injury after cardiac arrest in man
22. Serum neuron-specific enolase as early predictor of outcome after cardiac arrest
23. The association between blood lactate concentration on admission, duration of cardiac arrest, and functional neurological recovery in patients resuscitated from ventricular fibrillation
24. Sleep in critically ill patients requiring mechanical ventilation
25. The effect of earplugs on sleep measures during exposure to simulated intensive care unit noise
26. Intensive care unit psychosis, the therapeutic nurse-patient relationship and the influence of the intensive care setting: Analyses of interrelating factors
27. Development of delirium: A prospective cohort study in a community hospital
28. Drug-induced delirium: Incidence, management and prevention
29. The prognostic significance of delirium in older hospital patients
30. Critical illness polyneuropathy: A 2-year follow-up study in 19 severe cases
31. Critical illness polyneuropathy and myopathy (CIPNM): Evidence for local immune activation by cytokine expression in the muscle tissue
32. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis
33. Incidence and onset of critical illness polyneuropathy in patients with septic shock
34. Long-term outcome of critical illness polyneuropathy
35. Neurologic disorders in a medical intensive care unit
36. Status epilepticus: Risk factors and complications
37. Epidemiology and evidence for morbidity of nonconvulsive status epilepticus
38. Prevalence of nonconvulsive status epilepticus in comatose patients
39. Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring
40. Nonconvulsive status epilepticus in the critically ill elderly
41. A case of central cord syndrome caused by intubation: A case report
42. Transient nerve damage following intubation for trans-sphenoidal hypophysectomy
43. Succinylcholine does not change intracranial pressure, cerebral blood flow velocity, or the electroencephalogram in patients with neurologic injury
44. The effect of suxamethonium on intracranial pressure and cerebral perfusion pressure in patients with severe head injuries following blunt trauma
45. Effect of endotracheal suctioning on cerebral oxygenation in traumatic brain-injured patients
46. Effects of fiberoptic bronchoscopy on intracranial pressure in patients with brain injury: A prospective clinical study
47. Effects of varying levels of positive end-expiratory pressure on intracranial pressure and cerebral perfusion pressure
48. The Acute Respiratory Distress Syndrome Network
49. Correction of blood pH attenuates changes in hemodynamics and organ blood flow during permissive hypercapnia
50. The effects of inverse ratio ventilation on intracranial pressure: A preliminary report
51. Hyperventilation-induced cerebral ischemia in patients with acute brain lesions: Demonstration by xenon-enhanced CT
52. Renal replacement therapy for acute renal failure
53. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke
54. Thrombolytic therapy with streptokinase in acute ischemic stroke
55. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group
56. Tissue plasminogen activator for acute ischemic stroke
57. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke
58. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
59. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
60. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial. Stroke Treatment with Ancrod Trial
61. Defibrinogenating enzymes
62. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Prolyse in Acute Cerebral Thromboembolism
63. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial Prolyse in Acute Cerebral Thromboembolism